Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study to Evaluate the Safety and Efficacy of the Treatment With Pentostatin, Cyclophosphamide and Rituximab Followed by Rituximab Maintenance in Previously Untreated and Relapsed Patients With Immunocytoma/Morbus Waldenström, B-CLL and Other Indolent B-Cell Lymphomas

NCT00927797 is registered in ClinicalTrials.gov with Heidelberg University as lead sponsor.

NCT NCT00927797
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00927797 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study to Evaluate the Safety and Efficacy of the Treatment With Pentostatin, Cyclophosphamide and Rituximab Followed by Rituximab Maintenance in Previously Untreated and Relapsed Patients With Immunocytoma/Morbus Waldenström, B-CLL and Other Indolent B-Cell Lymphomas
Lead sponsor
Heidelberg University
Phase
Phase 2
Overall status
Unknown status
Start date
February 28, 2005
Completion date
January 31, 2012
Enrollment
185 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell chronic lymphocytic leukemia, b-cell non-hodgkin's lymphoma, immunocytoma/morbus waldenström